Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration

Background. Most patients with metastatic prostate cancer are endocrinologically treated with LHRH agonist, but finally castration-refractory and hormone-refractory cancers occur. Serum testosterone levels get low to “the castration level” by LHRH agonists but may not get low enough against castration-refractory prostate cancer. Methods. As case series, twelve patients suffering from hormone-refractory prostate cancer continuously on LHRH agonist underwent surgical castration. Additionally, one hundred and thirty-nine prostate cancer patients on LHRH agonist or surgical castration were tested for serum total testosterone levels. Results. Surgical castration caused decrease in serum PSA in one out of 12 hormone-refractory prostate cancer patients with PSA reduction rate 74%. Serum total testosterone levels were below the sensitivity threshold (0.05 ng/mL) in 40 of 89 (44.9%) medically castrated patients and 33 of 50 (66.0%) surgically castrated patients (P = .20). Conclusion. Even hormone-refractory prostate cancer patients are candidates for surgical castration because of endocrinological, oncological, and economical reasons.

• Publication year

  2011

• Venue

  Advances in Urology

• Publication date

  2011-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2012/979154PMID 21754927PMCID 3130489
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer

  2010cited by this paper
• Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients.

  2010cited by this paper
• Impact of Surgical and Medical Castration on Serum Testosterone Level in Prostate Cancer Patients

  2009cited by this paper
• Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.

  2007cited by this paper
• Bilateral orchidectomy in three metastatic prostate cancer patients with failed LHRH-agonist therapy.

  2006influential reference
• Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

  2002cited by this paper
• Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.

  2002cited by this paper
• Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.

  2000cited by this paper
• Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making.

  2000cited by this paper
• Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer.

  1997cited by this paper
• Ascites associated with antibiotic-associated pseudomembranous colitis.

  1997cited by this paper
• Extraglandular hormonal steroidogenesis in aged rats.

  1992cited by this paper
• Endocrine studies with a gonadotropin-releasing hormone analogue to achieve withdrawal of testosterone in prostate carcinoma patients.

  1982cited by this paper
• Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

  1941cited by this paper
• I. The Results of Double Castration in Hypertrophy of the Prostate.

  1895cited by this paper
• I. The Results of Double Castration in Hypertrophy of the Prostate.

  year unknowncited by this paper

• Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease

  2021cites this paper
• Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.

  2017cites this paper
• Bcl2 en cáncer avanzado de próstata y asociación con resistencia a la castración

  2016cites this paper
• Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective

  2016cites this paper
• Urological malignancy in Hong Kong: the trend and the practice.

  2015cites this paper
• Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy

  2015cites this paper
• Risk of new‐onset diabetes after androgen deprivation therapy for prostate cancer in the Asian population

  2015cites this paper
• Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.

  2014cites this paper
• Targeting the Androgen Receptor with Steroid Conjugates

  2014cites this paper
• Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer

  2014cites this paper
• Luteinizing hormone‐releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?

  2013cites this paper
• Eurycoma longifolia upregulates osteoprotegerin gene expression in androgen- deficient osteoporosis rat model

  2012cites this paper
• [Place of bilateral pulpectomy as a method of androgen suppression therapy in prostate cancer].

  2012cites this paper
• Androgen Deprivation Therapy for Advanced Prostate Cancer on the Ground of Androgen Milieu in the Prostate

  2012cites this paper
• Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.

  2012cites this paper